Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases

Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, announced the completion of a €72 million Series A financing.